# A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac

Source: https://onco.cc/trials/nct04414475/  
OnCo record `nct04414475` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Selinexor, Dexamethasone, Bortezomib in multiple myeloma, run by Karyopharm Therapeutics Inc, now recruiting.

## Summary

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. is a phase 2 interventional study registered as NCT04414475 by Karyopharm Therapeutics Inc, with 127 participants planned, started 2020-07-01 and due to reach its primary completion in 2028-01. Interventions recorded: Selinexor, Dexamethasone, Bortezomib. Conditions listed: Multiple Myeloma, Refractory. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04414475
- Phase: 2
- Setting: A Phase 2b, Open-label, Multi-arm Clinical Trial of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone (SVd) in Patients With Triple-class Refractory Multiple Myeloma
- Sponsor: Karyopharm Therapeutics Inc
- Enrolled: 127

## Sources

- ClinicalTrials.gov NCT04414475: https://clinicaltrials.gov/study/NCT04414475

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Bortezomib](https://onco.cc/drugs/bortezomib/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Selinexor](https://onco.cc/drugs/selinexor/)
- companies: [Karyopharm Therapeutics](https://onco.cc/companies/karyopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct04414475.json